The PreserFlo microshunt was given regulatory approval from the Therapeutic Goods Administration of Australia, according to a press release from Glaukos.
The microshunt is intended to reduce IOP in patients with primary open-angle glaucoma whose disease is uncontrolled on maximum medical therapy or whose disease progression warrants surgical intervention.
“We are delighted to receive regulatory approval from Australia’s TGA for the microshunt, marking a notable milestone in advancing our goal to bring this important late-stage glaucoma technology to ophthalmic surgeons and patients,”